Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
[email protected]

David Darst, M.B.A.

Chief Operating Officer

David co-leads Inspirna’s financing, business and corporate development, and drug development efforts. As COO, he is responsible for implementing the company’s strategic and operational objectives through its intellectual property generation and prosecution, licensing activities, budgeting, and cross-functional CMC, nonclinical, and clinical efforts. Prior to joining Inspirna, he was an investor at OrbiMed Advisors, the world’s largest private healthcare dedicated investment firm. There, he invested in leading private and publicly traded companies developing therapeutics for life-threatening and debilitating disorders.

David was a co-founder and Director of Potentia Pharmaceuticals, which spun out Apellis Pharmaceuticals (NASDAQ: APLS), which acquired its assets. Apellis’ complement inhibitor, pegcetacoplan, is an FDA approved drug for the treatment of geographic atrophy secondary to age-related macular degeneration (SYFOVRE) and paroxysmal nocturnal hemoglobinuria (EMPAVELI). David has an M.B.A. from Harvard Business School and a B.A., cum laude, from Harvard College. He is a former Director of the Alliance for Cancer Gene Therapy (ACGT) and sits on the Rockefeller University Advisory Council.